Merkliste
    FCI SAS

    LacriJet®

    LacriJet® is FCI latest and exclusive preloaded & self-retaining monocanalicular nasolacrimal intubation indicated for epiphora, congenital nasolacrimal duct obstruction and canalicular laceration.

    Weitere Produktinformationen

    LacriJet®

    FCI EXCLUSIVE

    LacriJet® is FCI latest and exclusive preloaded & self-retaining monocanalicular nasolacrimal intubation indicated for epiphora, congenital nasolacrimal duct obstruction and canalicular laceration.

    It consists of a single use injector handpiece into which a silicone tube is preloaded inside a metallic probe. LacriJet® has been specifically designed to reduce operating time, either in the intubation phase as well as for the removal of the device.

    Main characteristics:

    • Exclusive new injection system
    • Available in 7 lengths
    • 3 mm plug collarette
    • Sterile, Single use

    LacriJet® is a Class IIb medical device manufactured by FCI S.A.S. - Notified Body: GMED CE n°0459.


    Erhältlich bei:


    Produkt direkt anfragen: